-- CK0803 are neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells -- CK0803 represents the company's fifth program to receive IND Clearance utilizing Cellenkos' proprietary CRANEtechnology HOUSTON, Sept. 22, 2022 /PRNewswire/ -- Cellenkos, Inc., a clinical stage biotech company that focuses on developing transformative cellular therapeutics for treatment of inflammatory disorders and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 1 safety stu...